Pathology affecting the spinal cord structures and/or vertebral segments at the TLJ is not uncommon. Trauma is the most frequent cause of dysfunction-compression at these levels and may result in permanent neurological disability and vertebral column instability. Patients with TLJ pathology must be evaluated carefully and thoroughly with serial neurological examinations and diagnostic radiographic studies as outlined. The treatment of patients who are documented to harbor TLJ pathology must be individualized and is determined by the type, extent, and level of the lesion, the presence of dislocation and/or instability, and the degree of neurological compromise. Surgical decompression is the treatment of choice for patients with tumor or herniated disk. Many of the TLJ trauma patients may be managed nonoperatively, but surgical decompression and stabilization will be required in selected patients to maximize their long-term functional recovery. There are several viable surgical options and approaches available for the treatment of TLJ lesions, depending on individual patient pathology and the experience and expertise of the surgical team. In general, ventral compressive lesions, depending on individual patient pathology and the experience and expertise of the surgical team. In general, ventral compressive lesions must be approached via a ventral or ventrolateral exposure allowing decompression without injury to neural structures. In our experience, the "modified" costotransversectomy approach is an efficacious approach for treatment of TLJ pathology and incorporates both a decompression procedure and a stabilization-fusion procedure (when required) into the same operative setting.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tlj pathology
12
surgical decompression
8
treatment tlj
8
lesions depending
8
depending individual
8
individual patient
8
patient pathology
8
pathology experience
8
experience expertise
8
expertise surgical
8

Similar Publications

Introduction: Annual screening for hydroxychloroquine (HCQ) retinopathy is recommended, and electroretinography (ERG) is considered a gold-standard test, but there are screening shortfalls and standard ERG is burdensome and has limited availability. Newer, portable ERG devices using skin-based electrodes may increase screening capacity but need validation. This study aims to determine initial device accuracies and feasibility of further research.

View Article and Find Full Text PDF

Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant.

View Article and Find Full Text PDF

The ESOT TLJ 3.0. consensus conference brought together leading experts in transplantation to develop evidence-based guidance on the standardization and clinical utility of pre-implantation kidney biopsy in the assessment of grafts from Expanded Criteria Donors (ECD).

View Article and Find Full Text PDF

The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies.

Front Immunol

February 2023

Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, United States.

Introduction: Over the last decade, the field of systems vaccinology has emerged, in which high throughput transcriptomics and other omics assays are used to probe changes of the innate and adaptive immune system in response to vaccination. The goal of this study was to benchmark key technical and analytical parameters of RNA sequencing (RNA-seq) in the context of a multi-site, double-blind randomized vaccine clinical trial.

Methods: We collected longitudinal peripheral blood mononuclear cell (PBMC) samples from 10 subjects before and after vaccination with a live attenuated vaccine and performed RNA-Seq at two different sites using aliquots from the same sample to generate two replicate datasets (5 time points for 50 samples each).

View Article and Find Full Text PDF

Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models.

NPJ Vaccines

September 2022

Department of Pathology, The University of Texas Medical Branch at Galveston, 301 University Blvd, Galveston, TX, 77555, USA.

Article Synopsis
  • Rift Valley fever (RVF) is a disease spread by mosquitoes, mainly affecting regions in Africa and the Arabian Peninsula, causing significant outbreaks in both humans and livestock.
  • Single-dose vaccinations with a modified RVF virus, known as RVax-1, show promise in preventing the spread of the virus without allowing it to mutate into a harmful strain.
  • RVax-1 has been found to be safe and effective in a mouse model, providing strong immune protection while being unable to replicate in Aedes aegypti mosquitoes, making it a strong candidate for future vaccination efforts against RVF.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!